Free Trial
NASDAQ:NGNE

Neurogene Q4 2024 Earnings Report

Neurogene logo
$17.21 -1.53 (-8.16%)
Closing price 04:00 PM Eastern
Extended Trading
$17.00 -0.21 (-1.22%)
As of 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neurogene EPS Results

Actual EPS
-$0.99
Consensus EPS
-$1.04
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Neurogene Revenue Results

Actual Revenue
$0.93 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neurogene Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 24, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Neurogene's Q2 2025 earnings is scheduled for Friday, August 8, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Neurogene Earnings Headlines

Dalio heeds Buffett’s warning… [$319 million stake in gold]
Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profitable miners selling at deep discounts. I call this price gap the Golden Anomaly — and I’ve put together a full report on my top four picks.
Baird Downgrades Neurogene (NGNE)
See More Neurogene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neurogene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neurogene and other key companies, straight to your email.

About Neurogene

Neurogene (NASDAQ:NGNE), a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

View Neurogene Profile

More Earnings Resources from MarketBeat